Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMO-CARB: temocillin versus carbapenem for ESBL-related urinary tract infection
2017-001257-14Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of temocillin, meropenem, imipenem + cilastatin and ertapenem in urinary tract infection (UTI) and complicated urinary tract infection (cUTI) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite clinical and microbiological cure. Started Jan 2021; status: completed.
02
Drugs
temocillinmeropenemimipenem + cilastatinertapenem
03
Conditions
urinary tract infection (UTI)complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on 2017-001257-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001257-14.